Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond to first generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR T790M mutation....

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Walter, Annette O., Sjin, Robert Tjin Tham, Haringsma, Henry J., Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksander, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang, Sheets, Michael, Martin, Thia St, Karp, Russell, van Kalken, Dan, Chaturvedi, Prasoon, Niu, Deqiang, Nacht, Mariana, Petter, Russell C., Westlin, William, Lin, Kevin, Jaw-Tsai, Sarah, Raponi, Mitch, Dyke, Terry Van, Etter, Jeff, Weaver, Zoe, Pao, William, Singh, Juswinder, Simmons, Andrew D., Harding, Thomas C., Allen, Andrew
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4048995/
https://ncbi.nlm.nih.gov/pubmed/24065731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0314
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы